

Subject: Re: Biotech Update... Gilead beat, shares halted [C]

From: Tazia Smith <[REDACTED]>

Date: Tue, 22 Apr 2014 16:16:17 -0400

To: jeevacation@gmail.com

Cc: Nav Gupta <[REDACTED]> ,

Paul Morris <[REDACTED]> ,

[REDACTED] ,

Vahe Stepanian <[REDACTED]> ,

Vinit Sahni <[REDACTED]>

Classification: Confidential

Jeffrey - sure you see this, just making sure, Gilead shares are halted in the after-market following a significant top and bottom-line earnings beat (\$1.48 vs \$0.92 cons eps, \$5bn on the topline vs. expectations of \$3.96bn) as you know, you're long 8100 shares at an average price of \$79.41, stock closed today at \$72.86, just reported.

Shares expected to re-open at 4:30pm

From: Tazia Smith [REDACTED] To: jeevacation@gmail.com, Cc: Paul Morris, Vahe Stepanian [REDACTED], Nav Gupta [REDACTED], Vinit Sahni [REDACTED] [REDACTED], [REDACTED] Date: 04/02/2014 03:42 PM Subject: Biotech Update... [C]

Classification: Confidential

Jeffrey -

Biotech forming a base to some extent (strong market backdrop, clearly) - you're up \$906k on your basket excluding the Ariad (outlier due to M&A prospects vs. group drivers) 1-mo price history charts below.

SGMO 1mo Price History

BIIB 1mo Price History

GILD 1mo Price History

FMI 1mo Price History

Tazia Smith
Director | Key Client Partners - US

DB Securities Inc
Deutsche Asset & Wealth Management
345 Park Avenue, 10154-0004 New York, NY, USA
Tel. [REDACTED]
Fax [REDACTED]
Mobile [REDACTED]
Email [REDACTED]